Guaranteed rights issue of NOK 90 million

Posted on Jun 17, 2010

Lysaker, Norway, June, 2010. PCI Biotech Holding ASA (PCI Biotech) has strengthened the company’s equity by NOK 90 million through a share issue of 2,250,000 shares with pre-emptive subscription rights for existing shareholders. The rights issue was fully guaranteed. The subscription price in the rights issue was NOK 40 per share. The subscription period for […]

Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells.

Posted on Mar 16, 2010

Oslo, 16 March 2010 – PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. Complete clinical regression of all evaluable treated tumours is observed within a few weeks […]

PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex® trial. Strong anti-tumour response observed in all patients

Posted on Jan 19, 2010

Oslo, 19 January 2010 – PCI Biotech reported today that it has completed the treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. To date seven patients have been given a single photochemical internalisation (PCI) treatment of […]